Ventyx Biosciences Company Insiders
| VTYX Stock | USD 2.51 0.02 0.80% |
Slightly above 60% of all Ventyx Biosciences' insiders are taking a long position. The analysis of insiders' sentiment of trading Ventyx Biosciences stock suggests that some insiders are bullish at this time. Ventyx Biosciences employs about 81 people. The company is managed by 11 executives with a total tenure of roughly 189 years, averaging almost 17.0 years of service per executive, having 7.36 employees per reported executive.
Insider Sentiment 60
Mostly Buying
Selling | Buying |
Latest Trades
| 2024-12-27 | John Nuss | Disposed 21119 @ 2.36 | View | ||
| 2024-12-23 | Sheila Gujrathi | Acquired 130000 @ 2.31 | View | ||
| 2024-12-19 | John Nuss | Disposed 13161 @ 2.26 | View | ||
| 2024-11-25 | Raju Mohan | Acquired 261752 @ 2.01 | View | ||
| 2024-11-22 | Raju Mohan | Acquired 238248 @ 1.83 | View |
Monitoring Ventyx Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. Ventyx Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.292) % which means that it has lost $0.292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4604) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to rise to -0.53 in 2025. Net Tangible Assets is likely to rise to about 427.3 M in 2025, whereas Total Assets are likely to drop slightly above 223.3 M in 2025.Common Stock Shares Outstanding is likely to drop to about 60.6 M in 2025. Net Loss is likely to rise to about (92.7 M) in 2025
Ventyx Biosciences Workforce Comparison
Ventyx Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,842. Ventyx Biosciences claims roughly 81.0 in number of employees contributing just under 2% to equities under Health Care industry.
Ventyx Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ventyx Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ventyx Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ventyx Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-06-01 | 7.0 | 7 | 1 | 204,750 | 1,887 |
| 2025-03-01 | 2.25 | 9 | 4 | 1,488,179 | 3,087,131 |
| 2024-12-01 | 1.1667 | 7 | 6 | 980,532 | 384,812 |
| 2024-09-01 | 0.2 | 1 | 5 | 350,000 | 155,000 |
| 2024-06-01 | 0.7778 | 7 | 9 | 581,778 | 2,779,129 |
| 2024-03-01 | 3.25 | 13 | 4 | 715,436 | 25,436 |
| 2023-12-01 | 0.6667 | 12 | 18 | 1,234,578 | 452,163 |
| 2023-09-01 | 0.1538 | 14 | 91 | 238,485 | 5,367,836 |
| 2023-06-01 | 0.2727 | 21 | 77 | 287,613 | 4,605,307 |
| 2023-03-01 | 1.6 | 16 | 10 | 1,052,217 | 2,567,992 |
| 2022-12-01 | 0.2424 | 8 | 33 | 254,762 | 8,766,004 |
| 2022-06-01 | 6.0 | 18 | 3 | 942,058 | 63,389 |
| 2021-12-01 | 0.5517 | 16 | 29 | 44,797,357 | 48,629,309 |
Ventyx Biosciences Notable Stakeholders
A Ventyx Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ventyx Biosciences often face trade-offs trying to please all of them. Ventyx Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ventyx Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Raju Mohan | CEO, Founder | Profile | |
| Matthew Moore | Chief Officer | Profile | |
| Snehal Naik | Senior Development | Profile | |
| Kye MD | Data Biostatistics | Profile | |
| Sheila MD | Executive Chairperson | Profile | |
| John Nuss | Chief Officer | Profile | |
| Martin MD | Chief Officer | Profile | |
| Kathy Ogilvie | Senior Research | Profile | |
| Prof MD | Pres Officer | Profile | |
| Rosa Ferrao | Senior Affairs | Profile | |
| MBA JD | Chief Officer | Profile |
About Ventyx Biosciences Management Performance
The success or failure of an entity such as Ventyx Biosciences often depends on how effective the management is. Ventyx Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ventyx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ventyx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.56) | (0.53) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | (0.53) | (0.51) |
Please note, the imprecision that can be found in Ventyx Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ventyx Biosciences. Check Ventyx Biosciences' Beneish M Score to see the likelihood of Ventyx Biosciences' management manipulating its earnings.
Ventyx Biosciences Workforce Analysis
Traditionally, organizations such as Ventyx Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ventyx Biosciences within its industry.Ventyx Biosciences Manpower Efficiency
Return on Ventyx Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 12.3M | |
| Working Capital Per Employee | 2.7M | |
| Working Capital Per Executive | 19.7M |
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.